Division of Psychiatry, W1T 7NF and Institute for Health Informatics, UCL, NW1 2DA, UK.
Psychiatric Epidemiology, Division of Psychiatry, UCL, W1T 7NF and Camden and Islington NHS Foundation Trust, London NW1 0PE, UK.
Schizophr Res. 2018 Feb;192:219-225. doi: 10.1016/j.schres.2017.05.028. Epub 2017 Jun 7.
Severe mental illness (SMI) is associated with excess cardiovascular disease (CVD) morbidity, but little is known on provision of preventative interventions. We investigated statin initiation for primary CVD prevention in individuals with and without SMI.
We used primary care data from The Health Improvement Network from 2006 to 2015 for UK patients aged 30-99years with no pre-existing CVD conditions and selected individuals with schizophrenia (n=13,252) or bipolar disorder (n=11,994). In addition, we identified samples of individuals without schizophrenia (n=66,060) and bipolar disorder (n=59,765), but with similar age and gender distribution. Missing data on CVD covariates were estimated using multiple imputation. Statin prescribing differences between individuals with and without SMI were investigated using multivariable Poisson regression models.
Initiation of statin prescribing was between 2 and 3 fold higher in people aged 30-59years with SMI than in those without after adjusting for CVD covariates. The rates in those aged 60-74years with SMI were similar or slightly higher relative to those without SMI. The incidence rate ratio (IRR) was 1.15 (95% CI 1.03-1.28) for bipolar disorder and 1.00 (0.91-1.11) for schizophrenia. The rate of statin prescribing was lower (IRR 0.81 (0.66-0.98)) amongst the oldest (aged 75+years) with schizophrenia relative to those without schizophrenia.
Despite higher rates of new statin prescriptions to younger individuals with SMI relative to individuals without SMI, there was evidence of lower rates of statin initiation for older individuals with schizophrenia, and this group may benefit from additional measures to prevent CVD.
严重精神疾病(SMI)与心血管疾病(CVD)发病率过高有关,但对于预防干预措施的提供知之甚少。我们研究了在有和没有 SMI 的个体中启动他汀类药物进行主要 CVD 预防的情况。
我们使用 2006 年至 2015 年来自英国健康改善网络的初级保健数据,纳入年龄在 30-99 岁之间且无预先存在的 CVD 疾病的患者,并选择患有精神分裂症(n=13252)或双相情感障碍(n=11994)的个体。此外,我们还确定了没有精神分裂症(n=66060)和双相情感障碍(n=59765)但年龄和性别分布相似的个体样本。使用多重插补法估计 CVD 协变量的缺失数据。使用多变量泊松回归模型研究了有和没有 SMI 的个体之间他汀类药物处方差异。
调整 CVD 协变量后,年龄在 30-59 岁的 SMI 患者开始使用他汀类药物的比例比没有 SMI 的患者高 2 到 3 倍。年龄在 60-74 岁的 SMI 患者的比例与没有 SMI 的患者相似或略高。双相情感障碍的发病率比为 1.15(95%CI 1.03-1.28),精神分裂症为 1.00(0.91-1.11)。与没有精神分裂症的患者相比,年龄最大(75 岁及以上)的精神分裂症患者的他汀类药物处方率较低(发病率比 0.81(0.66-0.98))。
尽管有 SMI 的年轻个体新开出他汀类药物的比例相对较高,但有证据表明,年龄较大的精神分裂症患者开始使用他汀类药物的比例较低,这群人可能需要采取额外措施来预防 CVD。